Prometheus Biosciences stock ends after USD 200 deal

Prometheus Biosciences stock ended its public-market story in a USD 200-per-share cash transaction with Merck, valuing the biotechnology company at USD 10.8 billion. Pharmaphorum reported the agreement on April 16, 2023, making the completed takeover the central fact for anyone researching the RXDX symbol.

Merck set the cash value

The agreed consideration was USD 200 per share, while the transaction value reached USD 10.8 billion. Multiples dates the agreement to April 16, 2023 and describes the purchase as an all-cash deal that later closed in 2023.

The transaction also carried a quantified premium: 75 percent above Prometheus Biosciences' prior closing price. That spread explains why the deal, rather than quarterly execution, became the decisive valuation reference for the former listed company.

RXDX was a Nasdaq biotech

Before the takeover, Prometheus Biosciences operated in biotechnology and pursued precision-medicine products for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline combined therapeutic candidates with companion diagnostic products, giving the business a development profile rather than an established large-scale commercial revenue base.

Investing.com identifies RXDX as the Nasdaq symbol for Prometheus Biosciences and records the historical transaction-era price at USD 199.92. The same page identifies the company as a US biotechnology issuer and labels the quoted history as historical data.

The transaction is the key reference

For investors studying RXDX, the useful comparison is therefore between the USD 200 cash offer and the 75 percent premium, not between a current quote and a new earnings forecast. The figures describe a completed corporate action and should be read as historical transaction terms.

The deal also places the company in a different category from an actively traded biotechnology stock. Merck's acquisition transferred the value of Prometheus Biosciences from public-market pricing to an agreed cash consideration, while the underlying focus remained inflammatory bowel disease research and diagnostics.

RXDX transaction benchmark

The last major market benchmark was USD 200 per share in the Merck agreement announced on April 16, 2023, alongside a USD 10.8 billion valuation and a 75 percent premium to the prior close.